Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Approvals Digital Health Neurology

FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite

  • Analysis

Executive Summary

Otsuka plans a slow, measured launch of Abilify MyCite, developed with Proteus Health. The product includes an ingested sensor that sends a signal to a wearable patch and an app that tracks ingestion, activity and mood to potentially improve management of psychiatric care.

Table

View full table

Advertisement

Related Content

Pink Sheet
Keeping Track: A Second Straight Burst Of FDA Approvals
Pink Sheet
FDA's NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra
Pink Sheet
FDA Ushers In Era of New Drug Manufacturing Technologies
Scrip
Digitizing The Pill: Proteus Pioneer Explains How
Scrip
Abilify Ingestible-Sensor Pill Seeks To Revolutionize Adherence
Pink Sheet
Proteus Digital Health’s Ingestible Sensor Reports When Granny Takes Her Meds

Topics

Related Companies

Advertisement
Tags:
Approvals Digital Health Neurology
UsernamePublicRestriction

Register

PS121966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By